Verspoor, F. G. M. http://orcid.org/0000-0001-8027-5888
Mastboom, M. J. L.
Hannink, G.
Maki, R. G. http://orcid.org/0000-0002-9853-2528
Wagner, A. http://orcid.org/0000-0002-4384-9448
Bompas, E.
Desai, J. http://orcid.org/0000-0003-4246-9344
Italiano, A.
Seddon, B. M.
van der Graaf, W. T. A.
Blay, J.-Y. http://orcid.org/0000-0001-7190-120X
Brahmi, M.
Eberst, L.
Stacchiotti, S.
Mir, O.
van de Sande, M. A. J.
Gelderblom, H.
Cassier, P. A. http://orcid.org/0000-0003-3857-1688
Article History
Received: 14 November 2018
Accepted: 23 September 2019
First Online: 10 October 2019
Competing Interests
: RGM., AW., JYB., OM., PAC. received personal fees or honorarium for research support outside the submitted work as mentioned in the next paragraph and ‘international committee of medical journal editors form for disclosure of potential conflicts of interest’. All other authors received no financial support for the research and/or authorship of this article. R.G.M. was in the advisory board of Novartis and received consulting fees at some point during the treatment of these patients. AW received consulting fees from Eli Lilly and Five Prime Therapeutics, also he reported research support from Plexxikon, Daiichi-Sankyo, Five Prime Therapeutics, Karyopharm, and Eli Lilly to the institution (Dana Farber Cancer Institute). JYB received grants and honoraria from Roche and Novartis (CentreLéon Bérard). BS was in advisory boards of Plexicon and Lily within the last 2 years. SS reported research grants from Novartis and Daiichi-Sankyo to the institution (Istituto Nazionale Tumori). OM received personal fees from Astra-Zeneca, Amgen, Bayer, BMS, Eli-Lilly, Novartis, Pfizer, Roche, and Servier outside the submitted work. MAJS reported research grants from Daiichi Sankyo and Implantcast to the institution (Leiden University Medical Center). WTAG reported a research grant from Novartis to the institution (Radboud University Medical Center). HG reported a research grant from Novartis and Daiichi to the institution (Leiden University Medical Center). PAC reports grants and personal fees from Novartis, Roche, Amgen; non-financial support from Plexxikon; grants, personal fees and non-financial support from Astra Zeneca during the conduct of the study; grants from Bayer, BMS, MSD, Toray, Taiho, BluePrint and from Eli Lilly outside the submitted work. The other authors (FGMV, MJLM, GH, EB, JD, AI, MB and LE) have declared no conflicts of interest.